Assertio (ASRT) Newsfilter·2024-12-13 13:00Core Insights - Assertio Holdings, Inc. announced positive results from a clinical trial of Rolvedon® (eflapegrastim-xnst) injection for early stage breast cancer patients, presented at the San Antonio Breast Cancer Symposium [1][2] Group 1: Clinical Trial Results - The open-label, single-arm study involved 13 sites in the US, where patients received Rolvedon 30 minutes post-chemotherapy [2] - Rolvedon demonstrated a neutrophil count recovery time of 1.8 days and a febrile neutropenia rate of 2%, with no patients requiring hospitalization for febrile neutropenia [2] - No new safety signals were identified during the trial [2] Group 2: Company Statements - The CEO of Assertio expressed satisfaction with the trial results, emphasizing the potential of Rolvedon to improve the lives of patients undergoing chemotherapy [3] - The Senior Vice President of Medical highlighted the encouraging safety and efficacy profile of Rolvedon, supporting its potential to enhance patient outcomes and quality of life [4] Group 3: Company Overview - Assertio is a commercial pharmaceutical company with capabilities in marketing, market access, and distribution, built through acquisition or licensing of approved products [5]